Roger Sawhney

Roger Sawhney has served as our Chief Financial Officer since June 2024. Dr. Sawhney most recently served as the Chief Financial Officer of Garuda Therapeutics, Inc., a biotechnology company, from 2022 to 2023. Prior to this, Dr. Sawhney served in multiple positions, including Chief Business Officer and Chief Financial Officer, at Omega Therapeutics, Inc., a clinical-stage biotechnology company, from 2020 to 2022. Dr. Sawhney also served as Director of the healthcare investment platform at KKR & Co., a global investment firm, from 2018 to 2020, as Senior Vice President and Head of Global Corporate Strategy for Novartis AG, a public pharmaceutical company, from 2009 to 2012, as a Partner with Bain & Company, a management consulting firm, from 2012 to 2017, and as a Managing Director and subsequently as a Partner with the Boston Consulting Group, a management consulting firm, from 1996 to 2009. He currently serves as a director of SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company, since January 2024, previously served as a director of Arcellx, Inc., a clinical stage cell therapy company, from 2017 to 2020 and served as a trustee of NYIT (New York Institute of Technology) from 2015 to 2021. Dr. Sawhney earned an M.D. from Harvard Medical School and a B.A. in Economics from Stanford University.